Growth of UK facility will enable clinical-grade manufacturing of drug substances for range of biopharmaceutical products
BURLINGTON, Mass., Nov. 15, 2024 /PRNewswire/ -- SEKISUI Diagnostics' microbial CDMO business announces it has completed construction of its £15.7 million ($20.7 million) cGMP capacity expansion at its UK site for clinical-grade drug substance manufacturing. Following appropriate licensure, this expansion will enable manufacturing capabilities for common drug types including enzymes, proteins and antibody fragment therapies, as well as plasmids and enzymes for cutting-edge gene therapy manufacture.
BioProduction by SEKISUI is SEKISUI Diagnostics' contract service offering as a fermentation-focused CDMO with expertise in proteins and downstream purification. Their microbial process development and production experience helps smooth technical transfer and process scale-up. The new Grade C microbial fermentation and purification suites will accommodate production scales up to 1,000L.
"This investment supports the vision and mission of SEKISUI Diagnostics and the broader SEKISUI Medical Group by enabling the continued growth of our share of the biologics CDMO market," said Robert Schruender, President & CEO of SEKISUI Diagnostics. "We look forward to working with biopharma companies seeking an experienced partner at a time when demand is outstripping manufacturing capacity."
Louise Digby, Vice President, Enzymes & BioProduction at SEKISUI Diagnostics added: "Over many years we have honed our technical and operational competency and expertise in enzyme production and microbial fermentation to serve our partners globally. This cGMP expansion enables us to support a broader customer base and expand our offering to existing customers."
About SEKISUI Diagnostics
We are part of SEKISUI Medical Group with over 40 years of experience supplying innovative medical diagnostics globally to physicians, hospitals, laboratories and alternate testing locations. Our product lines include clinical chemistry reagents, point-of-care tests, pre-analytic systems as well as enzymes, specialty biochemicals and the microbial CDMO business, BioProduction by SEKISUI.
About SEKISUI Medical Group
SEKISUI Medical Group is a diverse, global network consisting of a diagnostics business and pharmaceutical sciences business which spans drug development services and manufacturing, including active pharmaceutical ingredients and pharmaceutical intermediates, amino acids, as well as a wide range of enzymes for use in diagnostics, and biopharmaceutical contract manufacturing and more.
Photo - https://mma.prnasia.com/media2/2552164/Fermentation_Gantry_2.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/412597/sekisui_diagnostics_logo.jpg?p=medium600
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
SEKISUI Completes £15.7 Million Expansion in cGMP Biopharma CDMO Capacity
NEW YORK, Nov. 14, 2024 /PRNewswire/ -- Paiseec, a leading brand in innovative mobility solutions, is transforming the wheelchair industry with its groundbreaking W3—a 3-in-1 device that enhances the mobility experience for wheelchair users.
Introducing the W3: The World's First 3-In-1 Electric Wheelchair
Paiseec has a wide range of mobility aids available to purchase, including mobility scooters, power wheelchairs, and rollators. Its newest offering, the W3 electric wheelchair, is specifically designed to cater to the varied needs of wheelchair users across different environments. The W3 seamlessly switches between three modes: a power wheelchair for daily mobility, an intelligent transport device, and a rollator for extended use, thus embodying the versatility of a single device serving multiple purposes.
3-in-1 Functionality
Engineered for Performance and Comfort
The award-winning W3, recognized by IF Design, features precision controls, smart sensor handles, and wheels with adjustable resistance to enhance safety. It boasts a durable battery and a user-friendly large-screen interface for effortless navigation, complemented by a robust motor for smooth uphill travel. Furthermore, the 12Ah battery ensures the wheelchair's compatibility with public transportation, making it easy to travel around. Designed with user comfort in mind, the W3 also provides ample legroom, an ergonomic seat, adjustable armrests, and high-quality wheels, that deliver a smooth ride across various road surfaces and terrains.
Customer Comes First
This high-performance electric wheelchair enables elderly and individuals with lower limb disabilities to live fuller lives, allowing them to partake in everyday activities. Equipped with the intelligent core technology of the PAI Safety System, the W3 exemplifies the principle that "smart technology equates to safe technology," offering a superior and empowering smart experience.
Paiseec provides exceptional after-sales service designed with customer satisfaction in mind. For products purchased through their official website, the company guarantees the following:
The W3 is available to purchase on the Paiseec official website for $2499.
"By integrating advanced technology with user-centric design, our W3 model disrupts traditional mobility solutions, offering unprecedented flexibility and independence to its users," said Roger Zhang, CEO of Paiseec. "We are not just creating mobility aids; we are redefining what mobility means with each innovation, making every day easier and safer for our users. Our commitment to technological advancement and user satisfaction sets a new standard in the industry."
About Paiseec
Paiseec stands at the forefront of mobility innovation, committed to delivering cutting-edge solutions for the elderly and disabled populations. Since its founding in 2021, the company has spearheaded a technological transformation in mobility assistance, creating an array of products such as mobility scooters, wheelchairs, and rollators that prioritize enhanced safety and intelligence.
To learn more, please visit www.paiseec.com.
Media Contact: media@paiseec.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Paiseec Launches the W3: A Revolutionary 3-in-1 Electric Wheelchair Signifying the Future of Mobility Solutions
